Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy.

Komatsu S, Hara N, Ishizaki F, Nishiyama T, Takizawa I, Isahaya E, Kawasaki T, Takahashi K.

Prostate. 2012 Aug 1;72(11):1207-13. doi: 10.1002/pros.22471. Epub 2011 Dec 27.

PMID:
22213519
2.

Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.

Ishizaki F, Hara N, Takizawa I, Nishiyama T, Isahaya E, Kawasaki T, Takahashi K.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):122-8. doi: 10.1016/j.ghir.2012.04.003. Epub 2012 May 11.

PMID:
22579549
3.

Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.

Hara N, Ishizaki F, Saito T, Nishiyama T, Kawasaki T, Takahashi K.

Urology. 2013 Feb;81(2):376-80. doi: 10.1016/j.urology.2012.10.050.

PMID:
23374809
4.

Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.

Hara N, Takizawa I, Isahaya E, Nishiyama T, Hoshii T, Ishizaki F, Takahashi K.

Urol Oncol. 2012 Sep;30(5):596-601. doi: 10.1016/j.urolonc.2010.11.001. Epub 2011 Apr 1.

PMID:
21458314
5.

Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.

Hara N, Nishiyama T, Takizawa I, Saito T, Kitamura Y, Takahashi K.

Urology. 2010 Jun;75(6):1441-5. doi: 10.1016/j.urology.2009.11.021. Epub 2010 Jan 29.

PMID:
20110105
6.

Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.

Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K.

Prostate. 2010 Sep 15;70(13):1395-401. doi: 10.1002/pros.21174.

PMID:
20687212
7.

Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.

Takizawa I, Hara N, Nishiyama T, Isahaya E, Hoshii T, Takahashi K.

J Urol. 2010 Nov;184(5):1971-6. doi: 10.1016/j.juro.2010.06.115.

PMID:
20884032
8.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
9.

Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.

Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K.

Prostate. 2010 Feb 1;70(2):155-61. doi: 10.1002/pros.21047.

PMID:
19760629
10.

Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer.

Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, Beer TM.

J Lipid Res. 2006 Feb;47(2):349-55. Epub 2005 Nov 20.

12.

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.

BJU Int. 2008 Jul;102(1):44-7. doi: 10.1111/j.1464-410X.2008.07539.x. Epub 2008 Mar 11. Erratum in: BJU Int. 2008 Aug;102(3):418.

13.

The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis.

Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM.

J Cancer Surviv. 2010 Jun;4(2):128-39. doi: 10.1007/s11764-009-0114-1. Epub 2010 Jan 21. Review.

PMID:
20091248
14.

Quality of life in prostate cancer patients taking androgen deprivation therapy.

Dacal K, Sereika SM, Greenspan SL.

J Am Geriatr Soc. 2006 Jan;54(1):85-90.

PMID:
16420202
15.

Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer.

Alberga AS, Segal RJ, Reid RD, Scott CG, Sigal RJ, Khandwala F, Jaffey J, Wells GA, Kenny GP.

Support Care Cancer. 2012 May;20(5):971-81. doi: 10.1007/s00520-011-1169-x. Epub 2011 May 3.

PMID:
21538098
16.

Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.

Verhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Cangh P, Mattelaer J, D'Hulster D, Mahler C.

Clin Endocrinol (Oxf). 1994 Oct;41(4):525-30.

PMID:
7525125
17.

Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids.

García-Fontana B, Morales-Santana S, Varsavsky M, García-Martín A, García-Salcedo JA, Reyes-García R, Muñoz-Torres M.

Osteoporos Int. 2014 Feb;25(2):645-51. doi: 10.1007/s00198-013-2462-y. Epub 2013 Aug 1.

PMID:
23903956
18.

Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.

Int J Biol Markers. 2005 Apr-Jun;20(2):119-22.

PMID:
16011042
19.

Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE.

Brachytherapy. 2010 Jan-Mar;9(1):42-9. doi: 10.1016/j.brachy.2009.06.008. Epub 2009 Oct 28.

PMID:
19875340
20.

Prostate cancer risk: the significance of differences in age related changes in serum conjugated and unconjugated steroid hormone concentrations between Arab and Caucasian men.

Kehinde EO, Akanji AO, Memon A, Bashir AA, Daar AS, Al-Awadi KA, Fatinikun T.

Int Urol Nephrol. 2006;38(1):33-44.

PMID:
16502050

Supplemental Content

Support Center